Leadership

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.